← Avalo Therapeutics, Inc. (AVTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Avalo Therapeutics, Inc. (AVTX)
Pharmaceutical Preparations · market cap $841M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Avalo Therapeutics (AVTX) is a 23-employee clinical-stage pharmaceutical company with a $957M market cap and four Phase 2 assets spanning chronic refractory cough, non-eosinophilic asthma, major depressive disorder, and hidradenitis suppurativa. The company carries only $25M in cash — roughly 4.2 months of runway — against a 2025 net loss of $78M and zero revenue, creating acute near-term financing pressure. The lead asset FP01 is in Phase 2 for chronic refractory cough; mechanism of action is undisclosed in available data.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| FP01 | Phase 2 | Chronic Refractory Cough |
| AVTX-002 | Phase 2 | Non-Eosinophilic Asthma |
| CERC-301 | Phase 2 | Major Depressive Disorder |
| AVTX-009 Regimen 1 | Phase 2 | Hidradenitis Suppurativa |
Price & technical context
3-month
-20.6%
6-month
-10.5%
12-month
+15.4%
52-wk range
$12.74–$22.87
vs 50-day MA
-17.9%
vs 200-day MA
-10.7%
Realized vol
80.6%
Max drawdown
-75.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AVTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.